# GUJARAT THEMIS BIOSYN LIMITED

**CIN: L24230GJ1981PLC004878**
REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail:hrm@gtbl.in.net


**GTBL/BSE/NSE/2026-27/45**

7th August, 2026

**Corporate Relationship Department**
**BSE Limited**
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

**Listing Department**
**National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

**Sub: Outcome of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

The Board of Directors at its meeting held today, have approved the Un-Audited Standalone & Consolidated Financial Results for the quarter ended 30th June, 2026. A copy of Un-Audited Standalone & Consolidated Financial Results for the quarter ended 30th June, 2026 together with the limited review reports of the Statutory Auditor is attached herewith.

The Board meeting commenced at 10.30 A.M (IST) and concluded at 12.55 P.M (IST).

The above is for your information and dissemination.

Thanking you,

Yours faithfully,

For **GUJARAT THEMIS BIOSYN LIMITED**

VINEET GANESH GAWANKAR
Digitally signed by VINEET GANESH GAWANKAR
Date: 2026.08.07 12:55:50 +05'30'

**Vineet Gawankar**
**Company Secretary & Compliance Officer**

**Encl.: a/a.**

GUJARAT THEMIS BIOSYN LIMITED
CIN: L24230GJ1981PLC004878
69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat
Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2026

(Amount in INR Lakhs)

| Sr. No. | PARTICULARS | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30.06.2026 (Unaudited) | 31.03.2026 (Audited) | 30.06.2025 (Unaudited) | 31.03.2026 (Audited) |
| I | Income from operations | 4,379.00 | 4,423.30 | 3,587.28 | 16,582.28 |
| II | Other Income | 13.17 | 92.11 | 27.44 | 242.81 |
| III | **Total Income (I+II)** | **4,392.16** | **4,515.41** | **3,614.72** | **16,825.09** |
| IV | Expenditure | | | | |
| | (a) Cost of raw material consumed | 772.91 | 1,005.48 | 682.59 | 3,042.86 |
| | (b) Purchases of stock-in-trade | - | - | - | - |
| | (c) Changes in inventories of Finished Goods,Work-in- Progress and Stock in Trade | (391.10) | (649.95) | (19.88) | (902.75) |
| | (d) Employee benefits expense | 472.13 | 379.40 | 311.19 | 1,651.06 |
| | (e) Finance Cost | 178.70 | 190.60 | 4.21 | 294.89 |
| | (f) Depreciation and Amortisation expenses | 397.29 | 403.84 | 203.38 | 1,291.93 |
| | (g) Other Expenses | | | | |
| | i) Stores and spares | 156.62 | 134.54 | 136.98 | 617.79 |
| | ii) Power | 672.20 | 792.37 | 517.66 | 2,458.86 |
| | iii) Fuel | 169.82 | 197.25 | 146.67 | 611.20 |
| | iv) Water | 26.49 | 34.65 | 28.60 | 118.81 |
| | v) Other expenditure | 420.58 | 593.58 | 391.36 | 1,431.44 |
| | **Total Expenses** | **2,875.63** | **3,081.76** | **2,402.76** | **10,616.08** |
| | | | | | |
| V | **Profit/(Loss) before Exceptional Items and Tax (III-IV)** | **1,516.53** | **1,433.65** | **1,211.96** | **6,209.00** |
| VI | Exceptional items | - | - | - | - |
| VII | **Profit/(Loss) before Tax (V-VI)** | **1,516.53** | **1,433.65** | **1,211.96** | **6,209.00** |
| | | | | | |
| VIII | **Tax expenses** | | | | |
| | (a) Current Tax | 271.66 | 237.55 | 246.64 | 1,078.63 |
| | (b) Deferred Tax | 138.20 | 106.98 | 59.16 | 462.23 |
| | (c) Income Tax of earlier years | - | - | - | - |
| IX | **Net Profit/(Loss) after tax (VII-VIII)** | **1,106.67** | **1,089.12** | **906.16** | **4,668.15** |
| X | **Other Comprehensive Income** | | | | |
| | **(A) Items that will not be reclassified to Profit or Loss** | | | | |
| | (i) remeasurement of defined benefit plans; | 0.17 | 0.56 | 1.70 | 0.67 |
| | (ii) Income Tax relating to items that will not be reclassified to Profit or Loss | (0.04) | (0.14) | (0.43) | (0.17) |
| | | | | | |
| | **(B) Items that will be reclassified to Profit or Loss** | - | - | - | - |
| | **Total Other Comprehensive income/(loss)** | 0.13 | 0.42 | 1.27 | 0.50 |
| | | | | | |
| XI | **Total Comprehensive Income for the period (IX+X)** | **1,106.80** | **1,089.54** | **907.44** | **4,668.65** |
| XII | Paid-up equity share capital | 1,089.65 | 1,089.65 | 1,089.65 | 1,089.65 |
| XIII | Other Equity | | | | 27,687.13 |
| XIV | **Earnings Per Share (Basic and Diluted)** | **1.02** | **1.00** | **0.83** | **4.28** |

Notes:

1 The above quarter ended June, 2026 unaudited standalone financial results have been reviewed by the Audit committee on 7th August, 2026 and approved by the Board of Directors. The Statutory Auditors have carried out an limited review of these financial results and given unmodified conclusion on the same.

2 The Company operates only in one Business Segment i.e. manufacturing of fermentation- based pharmaceutical intermediates and APIs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".

3 The above finanical results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendments thereafter.

4 The figures of the previous quarter ended March 31, 2026 are the balancing figures between audited figures of the full financial year and the published year-to-date figures for the nine months ended.

5 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

For GUJARAT THEMIS BIOSYN LIMITED

GUJARAT THEMIS BIOSYN LIMITED MUMBAI

Dr. DINESH PATEL
Chairman
DIN : 00033273

Place: Mumbai
Date : August 7, 2026

**GMJ & Co**
Chartered Accountants
3rd & 4th Floor, Vaastu Darshan,
'B'wing, Above Central Bank of India,
Azad Road, Andheri (East),
Mumbai - 400 069.
Tel. : 022- 6191 9293 / 222 /200
Fax : 022- 2684 2221 / 6191 9256
E-mail : admin@gmj.co.in
info@gmj.co.in

**Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results and Year to Date Results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Review report to**
**The Board of Directors**
**GUJARAT THEMIS BIOSYN LIMITED**

We have reviewed the accompanying statement of Unaudited Standalone financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For GMJ & Co**
Chartered Accountants
FRN: 103429W

GMJ & CO. MUMBAI FRN. NO. 103429W CHARTERED ACCOUNTANTS

**CA Amit Maheshwari**
Partner
M. No.: 428706
UDIN: 264287 06TJJA WG1746S

Place : Mumbai
Date : August 7, 2026

GUJARAT THEMIS BIOSYN LIMITED
CIN: L24230GJ1981PLC004878
69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat
Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026

(Amount in INR Lakhs)

| Sr. No. | PARTICULARS | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30.06.2026 (Unaudited) | 31.03.2026 (Audited) | 30.06.2025 (Unaudited) | 31.03.2026 (Audited) |
| I | Income from operations | 4,379.00 | 4,423.30 | 3,587.28 | 16,582.28 |
| II | Other Income | 13.17 | 92.11 | 27.44 | 242.81 |
| III | Total Income (I+II) | 4,392.16 | 4,515.41 | 3,614.72 | 16,825.09 |
| IV | Expenditure | | | | |
| | (a) Cost of raw material consumed | 772.91 | 1,005.48 | 682.59 | 3,042.86 |
| | (b) Purchases of stock-in-trade | - | - | - | - |
| | (c) Changes in inventories of Finished Goods,Work-in- Progress and Stock in Trade | (391.10) | (649.95) | (19.88) | (902.75) |
| | (d) Employee benefits expense | 472.13 | 379.40 | 311.19 | 1,651.06 |
| | (e) Finance Cost | 178.70 | 190.60 | 4.21 | 294.89 |
| | (f) Depreciation and Amortisation expenses | 397.29 | 403.84 | 203.38 | 1,291.93 |
| | (g) Other Expenses | | | | |
| | i) Stores and spares | 156.62 | 134.54 | 136.98 | 617.79 |
| | ii) Power | 672.20 | 792.37 | 517.66 | 2,458.86 |
| | iii) Fuel | 169.82 | 197.25 | 146.67 | 611.20 |
| | iv) Water | 26.49 | 34.65 | 28.60 | 118.81 |
| | v) Other expenditure | 420.58 | 593.58 | 391.36 | 1,431.44 |
| | Total Expenses | 2,875.63 | 3,081.76 | 2,402.76 | 10,616.08 |
| | | | | | |
| V | Profit/(Loss) before Exceptional Items and Tax (III-IV) | 1,516.53 | 1,433.65 | 1,211.96 | 6,209.00 |
| VI | Exceptional items | - | - | - | - |
| VII | Profit/(Loss) before Tax (V-VI) | 1,516.53 | 1,433.65 | 1,211.96 | 6,209.00 |
| | | | | | |
| VIII | Tax expenses | | | | |
| | (a) Current Tax | 271.66 | 237.55 | 246.64 | 1,078.63 |
| | (b) Deferred Tax | 138.20 | 106.98 | 59.16 | 462.23 |
| | (c) Income Tax of earlier years | - | - | - | - |
| IX | Net Profit/(Loss) after tax (VII-VIII) | 1,106.67 | 1,089.12 | 906.16 | 4,668.15 |
| X | Other Comprehensive Income | | | | |
| | (A) Items that will not be reclassified to Profit or Loss | | | | |
| | (i) remeasurement of defined benefit plans; | 0.17 | 0.56 | 1.70 | 0.67 |
| | (ii) Income Tax relating to items that will not be reclassified to Profit or Loss | (0.04) | (0.14) | (0.43) | (0.17) |
| | | | | | |
| | (B) Items that will be reclassified to Profit or Loss | - | - | - | - |
| | Total Other Comprehensive income/(loss) | 0.13 | 0.42 | 1.27 | 0.50 |
| | | | | | |
| XI | Total Comprehensive Income for the period (IX+X) | 1,106.80 | 1,089.54 | 907.44 | 4,668.65 |
| XII | Paid-up equity share capital | 1,089.65 | 1,089.65 | 1,089.65 | 1,089.65 |
| XIII | Other Equity | | | | 27,687.13 |
| XIV | Earnings Per Share (Basic and Diluted) | 1.02 | 1.00 | 0.83 | 4.28 |

Notes:

1 The above quarter ended June, 2026 unaudited consolidated financial results have been reviewed by the Audit committee on 7th August, 2026 and approved by the Board of Directors. The Statutory Auditors have carried out an limited review of these financial results and given unmodified conclusion on the same.

2 The Company operates only in one Business Segment i.e. manufacturing of fermentation- based pharmaceutical intermediates and APIs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".

3 The above finanical results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendments thereafter.

4 During the quarter ended 30th June 2026, the Company incorporated two wholly-owned subsidiaries outside India viz. Themis Biosyn Japan Limited (Japan) and Themis Biosyn Ireland Private Limited (Ireland). The subsidiaries have been consolidated from the respective dates on which control was obtained in accordance with Ind AS 110 "Consolidated Financial Statements". As the entities are yet to commence operations and no capital has been remitted, there is no impact on the consolidated financial results.

Since this is the first quarter in which the Company has prepared consolidated financial results pursuant to the incorporation of the subsidiaries, the comparative financial information for the quarter ended 31 March 2026, the corresponding quarter ended 30 June 2025 and the year ended 31 March 2026 represents the previously reported financial information of the Company. As no subsidiaries existed during those comparative periods, the comparative figures are identical to the standalone financial information previously reported and have not been restated.

5 The figures of the previous quarter ended March 31, 2026 are the balancing figures between audited figures of the full financial year and the published year-to-date figures for the nine months ended.

6 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

For GUJARAT THEMIS BIOSYN LIMITED

GUJARAT THEMIS BIOSYN LIMITED MUMBAI

Dr. DINESH PATEL
Chairman
DIN : 00033273

Place: Mumbai
Date : August 7, 2026

**GMJ & Co**
Chartered Accountants
3rd & 4th Floor, Vaastu Darshan,
'B'wing, Above Central Bank of India,
Azad Road, Andheri (East),
Mumbai - 400 069.
Tel. : 022- 6191 9293 / 222 /200
Fax : 022- 2684 2221 / 6191 9256
E-mail : admin@gmj.co.in
info@gmj.co.in

**Independent Auditor's Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To**
**The Board of Directors of**
**Gujarat Themis Biosyn Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Gujarat Themis Biosyn Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The accompanying Statement includes the interim financial information of the following subsidiaries:

   (i) Themis Biosyn Japan Limited (Japan)

   (ii) Themis Biosyn Ireland Private Limited (Ireland)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial information of two subsidiaries which have not been reviewed, whose interim financial information reflect total revenue of INR Nil, total profit after tax of INR Nil and total comprehensive income of INR Nil for the quarter ended June 30, 2026 as considered in the Statement. According to the information and explanations given to us by the Management and as disclosed in the Note no. 4 to the accompanying unaudited consolidated financial results, these interim financial information are not material to the Group. The comparative financial information represents the previously reported financial information of the Company for the respective periods when no subsidiaries existed and, accordingly, has not been restated.

   Our conclusion is not modified in respect of this matter.

**For GMJ & Co**
Chartered Accountants
FRN: 103429W

GMJ & CO. * MUMBAI FRN. NO. 103429W * CHARTERED ACCOUNTANTS

**CA Amit Maheshwari**
Partner
M. No.: 428706
UDIN: 264287 06JOSE VI2305

Place : Mumbai
Date : August 7, 2026